This Pharmaceutical Stock Is Leading the S&P 500 Higher Tuesday, After 'Remarkable' Trial Results

ETHReserveBank · 2026-03-14T18:42:42+00:00

Vertex Pharmaceuticals' shares rose over 8% after announcing promising Phase 3 trial results for its kidney disease drug, povetacicept, which achieved key goals and indicates potential approval and revenue growth, attracting positive analyst ratings.

ETHReserveBank

2026-03-14 18:42:42

Generación de resúmenes en curso

Key Takeaways

Vertex Pharmaceuticals shares surged Tuesday after announcing promising results from a clinical trial.
Analysts said the results could mark an important step for the company’s kidney disease medication.

Get personalized, AI-powered answers built on 27+ years of trusted expertise.

ASK

Vertex Pharmaceuticals (VRTX) shares are soaring after the company said it achieved “remarkable” results from a new clinical trial.

The stock was up over 8% to about $499 in recent trading, making it the best-performing stock in the S&P 500 Tuesday afternoon.

Vertex said Monday that a Phase 3 trial of its povetacicept accomplished both its primary and secondary goals, and reduced key markers of kidney disease compared to a placebo. The drug treats immunoglobulin A nephropathy (IgAN), a disorder that can lead to kidney damage or failure.

Why This Matters to Investors

Strong results from clinical trials can often boost a drugmaker’s stock, as they could be seen leading to revenue gains for the company.

Jefferies analysts on Tuesday initiated coverage of Vertex with a “buy” rating and $580 price target following the results, pointing to a growing market for IgAN drugs.

William Blair analysts, who hold an “outperform” rating for the stock, called the trial results a “clear win for Vertex.” The analysts said they now see the drug potentially being approved by the end of the year, and adding to revenue next year.

Most analysts with current ratings tracked by Visible Alpha are bullish on the stock. Their average price target around $563 would suggest analysts see the shares climbing to record highs in the next 12 months.

Related Education

Clinical Trials: What It Means, How It Works

Understanding Biotech Investing: Risks, Rewards, and Key Insights

Tuesday’s move higher leaves Vertex shares up more than 10% for 2026 so far, but still below their 2024 highs.

Do you have a news tip for Investopedia reporters? Please email us at

[email protected]

Esta página puede contener contenido de terceros, que se proporciona únicamente con fines informativos (sin garantías ni declaraciones) y no debe considerarse como un respaldo por parte de Gate a las opiniones expresadas ni como asesoramiento financiero o profesional. Consulte el Descargo de responsabilidad para obtener más detalles.